pGEX-5X-3-SARS-CoV-2-3CL Citations (2)

Originally described in: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Iketani S, Forouhar F, Liu H, Hong SJ, Lin FY, Nair MS, Zask A, Huang Y, Xing L, Stockwell BR, Chavez A, Ho DD Nat Commun. 2021 Apr 1;12(1):2016. doi: 10.1038/s41467-021-22362-2. PubMed Journal

---

Articles Citing pGEX-5X-3-SARS-CoV-2-3CL

Articles
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening. Liu H, Zask A, Forouhar F, Iketani S, Williams A, Vaz DR, Habashi D, Choi K, Resnick SJ, Hong SJ, Lovett DH, Bai T, Chavez A, Ho DD, Stockwell BR. Nat Commun. 2025 Jan 2;16(1):152. doi: 10.1038/s41467-024-55421-5. PubMed
A multiplex method for rapidly identifying viral protease inhibitors. Hong SJ, Resnick SJ, Iketani S, Cha JW, Albert BA, Fazekas CT, Chang CW, Liu H, Dagan S, Abagyan MR, Fajtova P, Culbertson B, Brace B, Reddem ER, Forouhar F, Glickman JF, Balkovec JM, Stockwell BR, Shapiro L, O'Donoghue AJ, Sabo Y, Freundlich JS, Ho DD, Chavez A. Mol Syst Biol. 2025 Feb;21(2):158-172. doi: 10.1038/s44320-024-00082-1. Epub 2025 Jan 6. PubMed

If you have published an article using this material, please email us at to have your article added to this page.